Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Indexes & Markets

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 

Stocks decline as COVID-19 cases surge

11/20/2020 | 05:55pm EST

The Dow and the S&P 500 suffered their first weekly losses in three weeks under the weight of a surge in coronavirus cases and what that could mean for the fragile economic recovery.

Blue chips fell 219 points on Friday. The S&P 500 lost 24. The Nasdaq reversed an early gain to fall 49 points.

Wall Street nerves were further frayed as Treasury Secretary Steven Mnunchin stands ready to allow funding for several Federal Reserve emergency lending programs to expire at the end of the year.

And yet, with the S&P 500 just 2 percent off a record high, Ken Kamen of Mercadien Asset Management is surprised the market is holding up as well as it has.

"I think also that the markets are, you know, dealing with a whole bunch of other things. I mean, we're really in a headline driven market and we're going to be that way. You know, it's kind of crazy when you think about how well the market's been doing when from the outside, with the election controversies, with the coronavirus surging and all that, you would think we wouldn't be here."

Drug stocks were in focus for more than one reason. Pfizer became the first company to apply for U.S. emergency authorization for a COVID-19 vaccine. The move came within the same week the drugmaker updated late-stage clinical trial results, which it said showed its vaccine was 95% effective in preventing the disease without any major complications. Shares of Pfizer rose 1.4 percent.

A different story, though, for Gilead Sciences. A World Health Organization panel advised against the use of Gilead's controversial COVID-19 treatment - Remdesivir, citing lack of evidence the drug improves the survival rate. The stock was down nearly a full percent.


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DJ INDUSTRIAL 0.13% 29910.37 Delayed Quote.4.67%
GILEAD SCIENCES, INC. 0.89% 60.03 Delayed Quote.-7.62%
NASDAQ 100 0.87% 12258.211779 Delayed Quote.39.15%
NASDAQ COMP. 0.92% 12205.846315 Delayed Quote.34.79%
PFIZER INC. 1.92% 37.23 Delayed Quote.0.30%
S&P 500 0.24% 3638.35 Delayed Quote.12.62%
Latest news "Markets"
11/27Wall Street Week Ahead: COVID-19 vaccine adoption rates are 'wildcard' for U.S. stock rally
RE
11/27TSX rises 0.32% to 17,406.89
RE
11/27WALL STREET STOCK EXCHANGE : S&P 500, Nasdaq End Week at Records
DJ
11/27EUROPE : European shares rise for fourth straight week; Spain's BBVA jumps
RE
11/27WALL STREET STOCK EXCHANGE : Wall Street rises, Nasdaq hits record high
RE
11/27WALL STREET STOCK EXCHANGE : Stocks on Track to End Week Near Records
DJ
11/27WALL STREET STOCK EXCHANGE : Stocks on Track to End Week Near Record Highs
DJ
11/27TSX falls on weakness in gold miners
RE
11/27TSX falls on weakness in gold miners
RE
11/27WALL STREET STOCK EXCHANGE : Nigeria's cocoa delivery for Q4 delayed at Lagos port
RE
Latest news "Markets"